(Q36660314)

15 August 2017

1 reference

title

Ondansetron. Therapeutic use as an antiemetic (English)

1 reference

15 August 2017

Milne RJ

1

1 reference

PubMed ID

1711961

15 August 2017

Heel RC

series ordinal

2

1 reference

15 August 2017

1 April 1991

1 reference

15 August 2017

1 reference

15 August 2017

41

1 reference

15 August 2017

4

1 reference

15 August 2017

574-595

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199141040-00006

15 August 2017

0 references

cites work

Extrapyramidal reactions with high-dose metoclopramide

1 reference

12 December 2020

GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis

1 reference

12 December 2020

A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy

1 reference

12 December 2020

The effect of x-irradiation on 5-hydroxytryptamine (serotonin) contents in the small intestines of experimental animals

1 reference

12 December 2020

Identification and distribution of 5-HT3 recognition sites within the human brainstem.

1 reference

12 December 2020

PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST

1 reference

12 December 2020

The metabolism of ondansetron

1 reference

12 December 2020

Two distinct effects of 5-hydroxytryptamine on single cortical neurons.

1 reference

12 December 2020

Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens

1 reference

12 December 2020

Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility

1 reference

12 December 2020

Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study

1 reference

12 December 2020

Metoclopramide-induced Parkinsonism. Clinical characteristics of ten cases

1 reference

12 December 2020

GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.

1 reference

12 December 2020

Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding.

1 reference

12 December 2020

Three serotonin responses in cultured mouse hippocampal and striatal neurons.

1 reference

12 December 2020

Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy

1 reference

12 December 2020

High dorsal column cordotomy plus subdiaphragmatic vagotomy prevents acute ionizing radiation sickness in cats

1 reference

12 December 2020

Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin

1 reference

12 December 2020

Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve

1 reference

12 December 2020

Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain.

1 reference

12 December 2020

Refractory vomiting with cisplatin therapy. Prospective study with the serotonin receptor antagonist GR 38032F

1 reference

12 December 2020

Blockade of 5-hydroxytryptamine3 receptors prevents cisplatin-induced but not motion- or xylazine-induced emesis in the cat

1 reference

12 December 2020

The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.

1 reference

12 December 2020

5-Hydroxytryptamine receptor subtypes

1 reference

12 December 2020

5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret

1 reference

12 December 2020

Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting

1 reference

12 December 2020

The effect of GR38032F, novel 5-HT3-receptor antagonist on gastric emptying in the guinea-pig

1 reference

12 December 2020

Neuropharmacology of Chemotherapy-induced Emesis

1 reference

12 December 2020

The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret

1 reference

12 December 2020

Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan

1 reference

12 December 2020

Correlation of anti-emetic efficacy and plasma levels of ondansetron

1 reference

12 December 2020

Serotonin raises the cyclic GMP level in a neuronal cell line via 5-HT3 receptors.

1 reference

12 December 2020

The determination in plasma and pharmacokinetics of ondansetron

1 reference

12 December 2020

5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment

1 reference

12 December 2020

A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group.

1 reference

12 December 2020

Safety of ondansetron

1 reference

12 December 2020

From metoclopramide to selective gut motility stimulants and 5-HT3 receptor antagonists.

1 reference

12 December 2020

Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist

1 reference

12 December 2020

Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides.

1 reference

12 December 2020

Ondansetron in the prophylaxis of nausea and vomiting induced by cisplatin

1 reference

12 December 2020

Physiology and pharmacology of vomiting

1 reference

12 December 2020

Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors

1 reference

12 December 2020

Two kinds of tryptamine receptor

1 reference

12 December 2020

Metoclopramide. An updated review of its pharmacological properties and clinical use.

1 reference

12 December 2020

Antiemetic properties of the 5HT3-receptor antagonist, GR38032F

1 reference

12 December 2020

Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy

1 reference

12 December 2020

Cisplatin-induced vomiting eliminated by ablation of the area postrema in cats

1 reference

12 December 2020

Differential modulation of three separate K-conductances in hippocampal CA1 neurons by serotonin

1 reference

12 December 2020

Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy

1 reference

12 December 2020

Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species

1 reference

12 December 2020

Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine

1 reference

12 December 2020

The 5-HT3 receptor ligand, [3H]BRL 43694, binds to presynaptic sites in the nucleus tractus solitarius of the rat

1 reference

12 December 2020

The properties of 5-HT3 receptors in clonal cell lines studied by patch-clamp techniques

1 reference

12 December 2020

Pharmacological and anti-emetic properties of ondansetron.

1 reference

12 December 2020

Serotonin regulates cytosolic Ca2+ activity and membrane potential in a neuronal and in a glial cell line via 5-HT3 and 5-HT2 receptors by different mechanisms.

1 reference

12 December 2020

Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors

1 reference

12 December 2020

Randomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting

1 reference

12 December 2020

Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia

1 reference

12 December 2020

Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis

1 reference

12 December 2020

[3H]zacopride: ligand for the identification of 5-HT3 recognition sites

1 reference

12 December 2020

Neuropharmacology of emesis induced by anti-cancer therapy.

1 reference

12 December 2020

Clinical studies with ondansetron in the control of radiation-induced emesis.

1 reference

12 December 2020

Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism

1 reference

12 December 2020

Evidence for presynaptic 5-hydroxytryptamine3 recognition sites on vagal afferent terminals in the brainstem of the ferret

1 reference

12 December 2020

Identification and characterisation of 5-hydroxytryptamine 3 recognition sites in human brain tissue.

1 reference

12 December 2020

Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret

1 reference

12 December 2020

Localization of 5-HT3 receptor binding sites in human dorsal vagal complex

1 reference

12 December 2020

The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties

1 reference

12 December 2020

GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting

1 reference

12 December 2020

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

12 December 2020

Optimum management of nausea and vomiting in cancer chemotherapy

1 reference

12 December 2020

Antiemetic efficacy and pharmacokinetic analyses of the serotonin antagonist ondansetron (GR 38032F) during multiple-day chemotherapy with cisplatin prior to autologous bone marrow transplantation

1 reference

12 December 2020

Prolonged metoclopramide-induced dyskinetic reaction

1 reference

12 December 2020

5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis

1 reference

12 December 2020

A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy

1 reference

12 December 2020

The clinical pharmacology of ondansetron

1 reference

12 December 2020

Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting

1 reference

12 December 2020

The neurophysiology of vomiting

1 reference

12 December 2020

Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation

1 reference

12 December 2020

ONDANSETRON WITH AND WITHOUT DEXAMETHASONE TO TREAT CHEMOTHERAPY-INDUCED EMESIS

1 reference

12 December 2020

Identification of 5-HT3 recognition sites in the ferret area postrema

1 reference

12 December 2020

[Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study]

1 reference

12 December 2020

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

1 reference

12 December 2020

Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.

1 reference

12 December 2020

Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.

1 reference

12 December 2020

10.2165/00003495-199141040-00006

Identifiers

DOI

1 reference

PubMed ID

1711961

Dimensions Publication ID

15 August 2017

0 references

1 reference

PubMed ID

1711961